Save this page
Save this page

My Saved Pages

  • Saved page.

My Saved Courses

  • Saved page.
Reset

Recently visited

  • Saved page.

Professor Yvonne Perrie

Strathclyde Institute of Pharmacy and Biomedical Sciences

Personal statement

In 1998, I gained my PhD from the University of London investigating the role of liposomes for drug delivery. I then moved to a newly established Drug Delivery Company (Lipoxen Technologies Ltd) for two years, developing their liposome drug delivery platform technology prior to moving to Academia to set up my own research group. I joined Aston University in 2000 and was appoint to Chair in Drug Delivery in 2007. I have effectively delivered in various academic and motivational leadership roles including Associate Dean for Learning and Teaching, Director of the Medicines Research Unit, and Head of Pharmacy.  In 2016, I moved to the University of Strathclyde at part of their Global Talent Appointment Programme where I am continuing to develop my research strategies.

My research is multi-disciplinary and is focused on the development of drug delivery systems to facilitate the delivery of drugs and vaccines, thus providing practical solutions for current healthcare problems. I am an internationally recognised researcher with a strong track-record of high impact publications (current h-index 30), with approximately 100 peer reviewed manuscripts and 5 textbooks. To ensure the effective knowledge exchange and application of my research, I have generated 5 patents. My research and academic leadership has been recognised in a range of fellowships and awards including membership of the Controlled Release Society College of Fellows (2015), Fellow of the Royal Pharmaceutical Society (2014), Fellow of the Royal Society of Biology (2012), Eminent Fellow of the Academy of Pharmaceutical Sciences (2012), the Royal Pharmaceutical Society Pharmaceutical Scientist of the Year (2012), the British Science Festival Collaboration in Formulation Award (2011) and the Royal Pharmaceutical Society Science Conference Medal (2007). I maintain a steady funding stream to support my research team and I am funded through a range of sources including Government Research Councils, European Framework Funding, Industrial Partners and Charities (>£3.5 million in research funding). I have supervised 22 PhD students to successful completion (< 4 years), all of whom are now further developing their careers in either Academic or Industrial positions.  Externally I have numerous strategic leadership and advisory roles: I am an expert advisor for the MHRA, Chair of Pharmacy Schools Council (Jan 2014-2017) and I am Editor of the Controlled Release Society Newsletter (2004 – present). Previously I have been a Director-at-Large for the Controlled Release Society (3 years) and I completed 2 terms (6 years) as the Chair for the UK and Ireland Controlled Release Society. I am Editor in Chief of the Journal of Liposome Research and Pharmaceutics and Associate Editor for the Journal of Drug Targeting and the Journal of Pharmacy and Pharmacology.

Publications

High potency of lipid conjugated TLR7 agonist requires nanoparticulate or liposomal formulation
Gadd Adam J.R., Castelletto Valeria, Kabova Elena, Shankland Kenneth, Perrie Yvonne, Hamley Ian, Cobb Alexander J.A., Greco F., Edwards Alexander D.
European Journal of Pharmaceutical Sciences Vol 123, pp. 268-276, (2018)
http://dx.doi.org/10.1016/j.ejps.2018.07.048
Metallosomes for biomedical applications by mixing molybdenum carbonyl metallosurfactants and phospholipids
Marín-García M., Benseny-Cases N., Camacho M., Perrie Y., Suades J., Barnadas-Rodríguez R.
Dalton Transactions, (2018)
http://dx.doi.org/10.1039/c8dt01584h
Anti-RSV peptide-loaded liposomes for the inhibition of respiratory syncytial virus
Joshi Sameer, Chaudhari Atul A., Dennis Vida, Kirby Daniel J., Perrie Yvonne, Singh Shree Ram
Bioengineering Vol 5, (2018)
http://dx.doi.org/10.3390/bioengineering5020037
Point of use production of liposomal solubilised products
Khadke Swapnil, Stone Peter , Rozhin Aleksey G., Kroonen Jerome , Perrie Yvonne
International Journal of Pharmaceutics Vol 537, pp. 1-8, (2018)
http://dx.doi.org/10.1016/j.ijpharm.2017.12.012
Application of pharmacokinetics modelling to predict human exposure of a cationic liposomal subunit antigen vaccine system
Badhan Raj K. S., Khadke Swapnil, Perrie Yvonne
Pharmaceutics Vol 9, (2017)
http://dx.doi.org/10.3390/pharmaceutics9040057
Nanomedicines : exploring the past, present and future
Perrie Yvonne, Ramsay Euan
Drug Discovery World Vol 18, pp. 17-22, (2017)

more publications

Projects

Microfluidic manufacturing and development of a novel clostridium difficile oral vaccine | Forbes, Neil Liam Andrew
Perrie, Yvonne (Principal Investigator) Hoskisson, Paul (Co-investigator) Forbes, Neil Liam Andrew (Research Co-investigator)
Period 01-Oct-2016 - 01-Oct-2019
Transfer of studentship for Maryan Hussien from UCL
Perrie, Yvonne (Principal Investigator)
Period 01-Apr-2016 - 19-Sep-2019
Microfluidic manufacturing and development of a novel clostridium difficile oral vaccine
Perrie, Yvonne (Principal Investigator)
Period 26-Sep-2016 - 25-Sep-2020
TBVAC2020 Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development (H2020 SC1 PHC)
Perrie, Yvonne (Principal Investigator)
Period 02-Apr-2016 - 02-Dec-2018
Leveraging Pharmaceutical Sciences and Structural Biology Training to develop 21st Century Vaccines PHA-ST-TRAIN-VAC (H2020 MCSA EID)
Perrie, Yvonne (Principal Investigator)
Period 01-Jun-2016 - 31-May-2020

more projects

Address

Strathclyde Institute of Pharmacy and Biomedical Sciences
Robertson Wing

Location Map

View University of Strathclyde in a larger map